BACK

CompuVax, Inc. announces the issuance of a second European patent covering key RSV antigens

10.10.18

CompuVax, Inc. announces the issuance of a second European patent covering key RSV antigens

Del Mar, October 10, 2018

CompuVax, Inc. announces the issuance of a second European patent on antigens against the respiratory syncytial virus engineered at Bill Schief's laboratory. European Patent No 2834263 claims improved variants of key epitope-scaffold immunogens in terms of size, stability, affinity, and resistance to mutant viruses. It was issued on October 10, 2018 and its duration is until April 4, 2033. This patent was issued to the University of Washington and is exclusively licensed worldwide to CompuVax, Inc.